ArticlePoultry science2026
Protective efficacy of Lactobacillus plantarum BS22 against Eimeria tenella and Eimeria acervulina co-infection in broiler chickens.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avian coccidiosis, caused by Eimeria spp., is a major constraint on global poultry production, and mixed-species infections-particularly Eimeria tenella and Eimeria acervulina-are common and more pathogenic in the broiler breeding. Rising concerns over anticoccidial drug resistance and residues have stimulated interest in probiotics as alternative or complementary control strategies. This study evaluated the protective efficacy of Lactobacillus plantarum BS22 (LP-BS22), a chicken-derived strain with confirmed in vitro antimicrobial activity and stability, against this clinically prevalent mixed infection. Seventy-two broiler chickens were randomly assigned to four groups: uninfected control (CG), probiotic control (LP-BS22), co-infected model (DIG), and probiotic-treated co-infected group (LP-BS22+DIG). Efficacy was assessed via growth performance, oocyst output, lesion scoring, and histopathology. To elucidate the underlying mechanism, the expressions of intestinal tight junction (TJ)-related zonula occluden-1 (ZO-1) and claudin 5 (CLDN5) proteins as well as pro-inflammatory (interleukin [IL]-6) and regulatory (IL-10 and IL-22) cytokines were also quantified. The results demonstrated that prophylactic administration of LP-BS22 significantly mitigated growth retardation, reduced fecal oocyst shedding, and lowered intestinal lesion scores compared to the untreated DIG group (P < 0.05). Histologically, the probiotic treatment alleviated intestinal villus atrophy and crypt hyperplasia. Mechanistically, LP-BS22 preserved intestinal barrier integrity by preventing the downregulation of ZO-1 and CLDN5; furthermore, the probiotic modulated the immune response by suppressing pro-inflammatory IL-6 while upregulating regulatory IL-10 and the tissue-repair cytokine IL-22 (P < 0.05). The calculated anticoccidial index (ACI) ranged from 126.76 to 133.46, classifying the efficacy as moderate. These findings indicated that LP-BS22 conferred protection against mixed Eimeria infections by enhancing mucosal barrier function and regulating inflammation, positioning it as a promising sustainable strategy for coccidiosis control in broiler production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.